LGND Q1 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+20.4% YoY

Gross Profit

$40M91.5% margin

Operating Income

$14M32.3% margin

Net Income

$42M95.4% margin

EPS (Diluted)

$2.33

QoQ Revenue Growth

+62.6%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$32M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$811M

Total Liabilities

$165M

Stockholders' Equity

$646M

Cash & Equivalents

$283M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$37M	+20.4%
Gross Profit	$40M	$32M	+26.5%
Operating Income	$14M	$2M	+566.0%
Net Income	$42M	-$15M	+372.7%

Revenue Segments

Royalty

$17M20%

Contract Revenue

$16M18%

Milestone

$15M17%

Material Sales, Captisol, Core

$11M12%

Material Sales, Captisol

$11M12%

Kyprolis

$6M7%

Teriparatide Injection

$4M4%

Rylaze

$3M3%

Evomela

$3M3%

Royalty, Other

$2M3%

License Fees, Milestones, and Product, Other, Product, Other

$789,0001%

License Fees

$114,0000%